Clinical Trial: Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06933056) titled 'Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs' on April 04.

Brief Summary: This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Platelet Function and Reactivity Tests

Intervention: DRUG: Sotagliflozin (SOTA) followed by 3 drugs in a random order

400 mg/day SOTA Each drug will be given daily for 2 weeks.

DRUG: Aspirin followed by 3 drugs in a random order

81 mg/day Aspirin Each drug will be given dai...